In Vitro Models for Glyconanoparticle Delivery Evaluation Service
Overview
Glyconanoparticles, adorned with carbohydrate molecules, enhance their biocompatibility and targeting capabilities, making them ideal for drug delivery, vaccine development, and targeting specific cells like cancer cells. Through a detailed evaluation of their drug delivery efficiency, safety, and cell interactions using various in vitro models, we optimize glyconanoparticle formulations, facilitating their transition to targeted therapeutic applications. CD BioGlyco, leveraging the established GlycoNano™ Platform, offers a customizable in vitro model-based evaluation service for glyconanoparticle delivery. These comprehensive Preclinical Studies provide reliable support for the use of glyconanoparticles in biomedical and drug-delivery contexts.
Your Most Satisfied Partner for In Vitro Models for Glyconanoparticle Delivery Evaluation
We offer a range of in vitro cell models specifically designed for testing and evaluating the potential of glyconanoparticles in targeted drug delivery. These models are crucial in studying and developing efficient therapeutic approaches. Our overall service process encompasses the following key steps:
Development of Glyconanoparticle
We rationalize the design of glyconanoparticles based on monomer composition, synthesis method, detailed application, etc. After the synthesis of glyconanoparticles, unreacted compounds, and other impurities are removed by dialysis, centrifugation, etc., to obtain high-quality glyconanoparticles. The size of glyconanoparticle is the most important parameter to determine cell uptake, drug loading, and delivery efficiency. We optimize to achieve minimum size and maximum loading.
Characterization of Glyconanoparticle
After preparation, we performed a comprehensive and detailed characterization of glyconanoparticles for rational analysis of glyconanoparticles in drug-targeted delivery. The characterization of glyconanoparticle includes but is not limited to the following:
- Measurement of the particle size and size distribution of glyconanoparticles by dynamic light scattering (DLS)
- Morphological study of glyconanoparticles by scanning electron microscope (SEM) and atomic force microscopy (AFM)
- Structural characterization of glyconanoparticles by Fourier transform infrared spectroscopy (FTIR), and nuclear magnetic resonance (NMR)
In Vitro Preclinical Studies of Glyconanoparticle
Available in vitro models include specific cancer cell lines expressing the targeted glycan receptor and normal cell lines to better mimic in vivo conditions. In addition to the models below, if you have other in vitro cell models of interest, our dedicated team offers model customization services to meet your research needs.
| HeLa cell-based glyconanoparticle delivery evaluation | RAW 264.7 cell-based glyconanoparticle delivery evaluation |
| MCF-7 cell-based glyconanoparticle delivery evaluation | L929 cell-based glyconanoparticle delivery evaluation |
| A549 cell-based glyconanoparticle delivery evaluation | PC3 cell-based glyconanoparticle delivery evaluation |
| H460 cell-based glyconanoparticle delivery evaluation | PC12 cell-based glyconanoparticle delivery evaluation |
| MDA-MB-231-based glyconanoparticle delivery evaluation | MDCK cell-based glyconanoparticle delivery evaluation |
| iPSCs-based glyconanoparticle delivery evaluation | CHO cell-based glyconanoparticle delivery evaluation |
| HMSCs-based glyconanoparticle delivery evaluation | DC2.4 cell-based glyconanoparticle delivery evaluation |
| HEK293 cell-based glyconanoparticle delivery evaluation | SH-SY5Y cell-based glyconanoparticle delivery evaluation |
| NRK-52E cell-based glyconanoparticle delivery evaluation | SKOV3 cell-based glyconanoparticle delivery evaluation |
| HUVECs-based glyconanoparticle delivery evaluation | MC3T3-E1 cell-based glyconanoparticle delivery evaluation |
| 3T3-L1 cell-based glyconanoparticle delivery evaluation | U87MG cell-based glyconanoparticle delivery evaluation |
| THP-1 cell-based glyconanoparticle delivery evaluation | Calu-3 cell-based glyconanoparticle delivery evaluation |
| HCT-116 cell-based glyconanoparticle delivery evaluation | COS-7 cell-based glyconanoparticle delivery evaluation |
| HepG2 cell-based glyconanoparticle delivery evaluation | HaCaT cell-based glyconanoparticle delivery evaluation |
| Caco-2 cell-based glyconanoparticle delivery evaluation | BEAS-2B cell-based glyconanoparticle delivery evaluation |
- After binding glyconanoparticles to a drug, their ability to enter cells is assessed by in vitro cell assays (flow cytometry, fluorescent labeling, etc.). The interactions between glyconanoparticles and cells, including cell uptake, internalization pathways, and intracellular distribution, are also studied. These analyses reveal the delivery mechanism of glyconanoparticles as drug carriers.
- The release rate and release profile of glyconanoparticle-encapsulated drugs are evaluated in vitro under simulated physiological conditions, and data are provided to support further understanding of drug release behavior in vivo.
- We assess the biological activity of the released drug on cells, including the effects on cell survival, morphology, cell proliferation, and apoptosis.
- We assess the toxic effects of glyconanoparticles and the drugs they carry on cells by assaying indicators such as cell survival, apoptosis, and changes in cell morphology. The immune response to glyconanoparticles is assessed by detecting cytokine release, etc.
Workflow
We provide a professional glyconanoparticle drug delivery assessment service based on various in vitro cell models to optimize glyconanoparticle formulations and advance targeted therapy research. In addition, we also provide comprehensive analytical support including statistical analysis, data-based optimization of glyconanoparticle formulations, and actionable insights for further research.

Applications
- Our in vitro cell model is used to evaluate the efficiency and specificity of glyconanoparticle delivery of therapeutic agents to target cells. Through the rational design and modification of glyconanoparticles, researchers can enhance drug uptake by cells expressing the corresponding receptors.
- Our in vitro cell model is used to study the kinetic characteristics of glyconanoparticles for drug release, thereby optimizing the particle design for sustained or triggered release of therapeutic drugs.
- Our in vitro cell models are used to evaluate the potential of glyconanoparticles to deliver RNA or DNA in gene therapy.
Advantages
- Our years of proven experience in cell culture and glyconanoparticle application evaluation ensures customized experimental protocols and maximum satisfaction with our client's research needs.
- We provide one-stop glyconanoparticle research services, including glyconanoparticle design, preparation, characterization, and drug delivery evaluation using in vitro models.
- Our professional team of data analysts is responsible for the detailed analysis of data and writing of study reports.
Publication Data
Technology: Polyelectrolyte complex (PEC) method, FTIR、NMR、DLS
Journal: DARU Journal of Pharmaceutical Sciences
IF: 1.653
Published: 2016
Results: In the present study, chitosan-coated hyaluronic acid-dosage paclitaxel nanoparticles were developed by the PEC method. The formation of this nanoparticle was confirmed by FTIR, NMR, UV spectroscopy, and DLS, and its morphology and stability were characterized. Biological evaluation of the nanoparticles was carried out using four T1, MCF-7 cell lines, and CD44+ cancer cells. The results showed that the IC50 of the nanoparticles was 45.34 μM and 354.25 μM, respectively, and they were more effective than free doxorubicin against CD44+ cells. Due to the higher cell uptake of the nanoparticles, the nanomaterials developed in this study can be used as a new drug delivery system to effectively bring loaded drug molecules into the cytoplasm.
Frequently Asked Questions
- What cell uptake studies do you perform?
We perform a variety of cell uptake studies using flow cytometry, laser confocal microscopy, and other techniques to quantify and observe the uptake of glyconanoparticles by target cells. - How do you assess the cytotoxicity of glyconanoparticles?
We use a variety of cytotoxicity assays, including MTT, LDH release, Annexin V/PI assay, etc., to assess the effects of glyconanoparticles on cell viability and apoptosis.
CD BioGlyco specializes in evaluating glyconanoparticle drug delivery using various in vitro models, which is essential for advancing the development of drug delivery systems and the study of various therapeutic strategies. Please feel free to contact us to discuss further experimental information if you are interested in this area or have any special requirements. We look forward to helping you better explore the potential applications of glyconanoparticles.
Reference
- Shabani Ravari, N.; et al. Fabrication and biological evaluation of chitosan coated hyaluronic acid-docetaxel conjugate nanoparticles in CD44+ cancer cells. DARU Journal of Pharmaceutical Sciences. 2016, 24: 1-12.
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





